Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy.

ABSTRACT

In this issue of Cell Chemical Biology, Lane et al.1 introduce a transgene-based system to express fusion proteins that recruit transcription factors to E3 ligases. This approach expands the target repertoire for engineered cell therapies as exemplified by the targeting of SMAD proteins to overcome a TGFß-mediated suppressive mechanism that weakens anti-tumor responses.